Despite initial challenges, several ongoing clinical trials are investigating the use of CTLA-4 or PD-1/PD-L1 inhibitors in castration-sensitive prostate cancer and low disease burden when the host is presumed to have a stronger immune system (NCT03007732). This evidence concerns the gene CTLA4 and prostate cancer.